Acute Effect of Pamidronate on PTH Secretion in Postmenopausal Hemodialysis Patients with Secondary Hyperparathyroidism

Kuo Cheng Lu, Lai King Yeung, Shih Hua Lin, Yuh Feng Lin, Pauling Chu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism. Methods: Twelve postmenopausal women undergoing regular hemodialysis with serum intact PTH levels greater than 200 pg/mL (200 ng/L) were included in this study. Pamidronate was administered intravenously as a single dose of 15 mg in the last hour of hemodialysis. PTH responses to hypocalcemia and hypercalcemia induced with 1 mEq/L (0.5 mmol/L) and 4 mEq/L (2 mmol/L) of dialysate calcium, respectively, were evaluated before and 1 week after pamidronate therapy. Results: Pamidronate therapy resulted in a decrease in predialysis basal plasma iCa (iCabase; P <0.05) levels and an increase in maximal serum PTH (PTHmax; P <0.001), basal PTH (PTHbase; P <0.001), and minimal PTH levels (P <0.001). The set point of serum calcium and the slope of the PTH-calcium curve were not altered by pamidronate therapy. An inverse correlation was present between iCabase and the PTHbase-PTHmax ratio before (r = -0.66; P <0.05) and after (r = -0.84; P <0.001) pamidronate therapy. Conclusion: Our study shows that pamidronate therapy is associated with reduced plasma iCa levels and increased PTH secretion, resulting in aggravated secondary hyperparathyroidism. These findings suggest that secondary hyperparathyroidism may worsen after the administration of pamidronate, at least in the short term, in postmenopausal hemodialysis patients.

Original languageEnglish
Pages (from-to)1221-1227
Number of pages7
JournalAmerican Journal of Kidney Diseases
Volume42
Issue number6
DOIs
Publication statusPublished - Dec 2003
Externally publishedYes

Fingerprint

pamidronate
Secondary Hyperparathyroidism
Parathyroid Hormone
Renal Dialysis
Calcium
Serum
Therapeutics
Hypocalcemia
Dialysis Solutions
Hypercalcemia

Keywords

  • Bisphosphonate
  • Calcium set point
  • Hemodialysis (HD)
  • Pamidronate
  • Postmenopausal
  • Secondary hyperparathyroidism
  • Uremia

ASJC Scopus subject areas

  • Nephrology

Cite this

Acute Effect of Pamidronate on PTH Secretion in Postmenopausal Hemodialysis Patients with Secondary Hyperparathyroidism. / Lu, Kuo Cheng; Yeung, Lai King; Lin, Shih Hua; Lin, Yuh Feng; Chu, Pauling.

In: American Journal of Kidney Diseases, Vol. 42, No. 6, 12.2003, p. 1221-1227.

Research output: Contribution to journalArticle

@article{231d96001f4c4fbf9a212f4d4cf5512b,
title = "Acute Effect of Pamidronate on PTH Secretion in Postmenopausal Hemodialysis Patients with Secondary Hyperparathyroidism",
abstract = "Background: The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism. Methods: Twelve postmenopausal women undergoing regular hemodialysis with serum intact PTH levels greater than 200 pg/mL (200 ng/L) were included in this study. Pamidronate was administered intravenously as a single dose of 15 mg in the last hour of hemodialysis. PTH responses to hypocalcemia and hypercalcemia induced with 1 mEq/L (0.5 mmol/L) and 4 mEq/L (2 mmol/L) of dialysate calcium, respectively, were evaluated before and 1 week after pamidronate therapy. Results: Pamidronate therapy resulted in a decrease in predialysis basal plasma iCa (iCabase; P <0.05) levels and an increase in maximal serum PTH (PTHmax; P <0.001), basal PTH (PTHbase; P <0.001), and minimal PTH levels (P <0.001). The set point of serum calcium and the slope of the PTH-calcium curve were not altered by pamidronate therapy. An inverse correlation was present between iCabase and the PTHbase-PTHmax ratio before (r = -0.66; P <0.05) and after (r = -0.84; P <0.001) pamidronate therapy. Conclusion: Our study shows that pamidronate therapy is associated with reduced plasma iCa levels and increased PTH secretion, resulting in aggravated secondary hyperparathyroidism. These findings suggest that secondary hyperparathyroidism may worsen after the administration of pamidronate, at least in the short term, in postmenopausal hemodialysis patients.",
keywords = "Bisphosphonate, Calcium set point, Hemodialysis (HD), Pamidronate, Postmenopausal, Secondary hyperparathyroidism, Uremia",
author = "Lu, {Kuo Cheng} and Yeung, {Lai King} and Lin, {Shih Hua} and Lin, {Yuh Feng} and Pauling Chu",
year = "2003",
month = "12",
doi = "10.1053/j.ajkd.2003.08.023",
language = "English",
volume = "42",
pages = "1221--1227",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Acute Effect of Pamidronate on PTH Secretion in Postmenopausal Hemodialysis Patients with Secondary Hyperparathyroidism

AU - Lu, Kuo Cheng

AU - Yeung, Lai King

AU - Lin, Shih Hua

AU - Lin, Yuh Feng

AU - Chu, Pauling

PY - 2003/12

Y1 - 2003/12

N2 - Background: The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism. Methods: Twelve postmenopausal women undergoing regular hemodialysis with serum intact PTH levels greater than 200 pg/mL (200 ng/L) were included in this study. Pamidronate was administered intravenously as a single dose of 15 mg in the last hour of hemodialysis. PTH responses to hypocalcemia and hypercalcemia induced with 1 mEq/L (0.5 mmol/L) and 4 mEq/L (2 mmol/L) of dialysate calcium, respectively, were evaluated before and 1 week after pamidronate therapy. Results: Pamidronate therapy resulted in a decrease in predialysis basal plasma iCa (iCabase; P <0.05) levels and an increase in maximal serum PTH (PTHmax; P <0.001), basal PTH (PTHbase; P <0.001), and minimal PTH levels (P <0.001). The set point of serum calcium and the slope of the PTH-calcium curve were not altered by pamidronate therapy. An inverse correlation was present between iCabase and the PTHbase-PTHmax ratio before (r = -0.66; P <0.05) and after (r = -0.84; P <0.001) pamidronate therapy. Conclusion: Our study shows that pamidronate therapy is associated with reduced plasma iCa levels and increased PTH secretion, resulting in aggravated secondary hyperparathyroidism. These findings suggest that secondary hyperparathyroidism may worsen after the administration of pamidronate, at least in the short term, in postmenopausal hemodialysis patients.

AB - Background: The purpose of this study is to evaluate the acute effect of pamidronate on plasma ionized calcium (iCa) level reduction and dynamic parathyroid hormone (PTH) secretion in postmenopausal hemodialysis-dependent women with secondary hyperparathyroidism. Methods: Twelve postmenopausal women undergoing regular hemodialysis with serum intact PTH levels greater than 200 pg/mL (200 ng/L) were included in this study. Pamidronate was administered intravenously as a single dose of 15 mg in the last hour of hemodialysis. PTH responses to hypocalcemia and hypercalcemia induced with 1 mEq/L (0.5 mmol/L) and 4 mEq/L (2 mmol/L) of dialysate calcium, respectively, were evaluated before and 1 week after pamidronate therapy. Results: Pamidronate therapy resulted in a decrease in predialysis basal plasma iCa (iCabase; P <0.05) levels and an increase in maximal serum PTH (PTHmax; P <0.001), basal PTH (PTHbase; P <0.001), and minimal PTH levels (P <0.001). The set point of serum calcium and the slope of the PTH-calcium curve were not altered by pamidronate therapy. An inverse correlation was present between iCabase and the PTHbase-PTHmax ratio before (r = -0.66; P <0.05) and after (r = -0.84; P <0.001) pamidronate therapy. Conclusion: Our study shows that pamidronate therapy is associated with reduced plasma iCa levels and increased PTH secretion, resulting in aggravated secondary hyperparathyroidism. These findings suggest that secondary hyperparathyroidism may worsen after the administration of pamidronate, at least in the short term, in postmenopausal hemodialysis patients.

KW - Bisphosphonate

KW - Calcium set point

KW - Hemodialysis (HD)

KW - Pamidronate

KW - Postmenopausal

KW - Secondary hyperparathyroidism

KW - Uremia

UR - http://www.scopus.com/inward/record.url?scp=0344826837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344826837&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2003.08.023

DO - 10.1053/j.ajkd.2003.08.023

M3 - Article

C2 - 14655194

AN - SCOPUS:0344826837

VL - 42

SP - 1221

EP - 1227

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -